BillionToOne Inc (BLLN)

Currency in USD
87.08
-9.22(-9.58%)
Closed·
87.11+0.03(+0.03%)
·
Trading near 52-week Low
BLLN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
86.2896.92
52 wk Range
86.28138.70
Key Statistics
Prev. Close
87.08
Open
95.52
Day's Range
86.28-96.92
52 wk Range
86.28-138.7
Volume
208.71K
Average Volume (3m)
244.15K
1-Year Change
-
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BLLN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
137.83
Upside
+58.28%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

BillionToOne Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

BillionToOne Inc Company Profile

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.

BillionToOne Inc Earnings Call Summary for Q3/2025

  • BillionToOne reported Q3 2025 revenue of $83.5M (117% YoY growth), with EPS of $0.10 and positive GAAP operating income of $9.6M, driving a 3.19% stock increase in aftermarket trading.
  • Prenatal segment revenue reached $74.1M (101% growth), while oncology revenue surged 664% to $8.7M; gross margin expanded 17 percentage points to 70%.
  • The company issued FY2025 revenue guidance of $293-299M (92-96% YoY growth) and expects Q4 revenue between $84-90M with continued positive GAAP operating income.
  • CEO Ozan Atey outlined plans to launch an MRD test by end of 2026 and expand Medicare coverage for Northstar Response, positioning BillionToOne as 'a category-defining generational company.'
Last Updated: 2025-12-09, 05:42 p/m
Read Full Transcript

Compare BLLN to Peers and Sector

Metrics to compare
BLLN
Peers
Sector
Relationship
P/E Ratio
−359.4x−0.1x−0.6x
PEG Ratio
-0.070.00
Price/Book
−16.6x0.8x2.6x
Price / LTM Sales
15.7x1.4x3.2x
Upside (Analyst Target)
50.6%29.7%41.8%
Fair Value Upside
Unlock3.6%5.1%Unlock

Analyst Ratings

5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 137.83
(+58.28% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy145.00+66.51%150.00MaintainDec 10, 2025
Piper Sandler
Buy150.00+72.26%-MaintainDec 10, 2025

Earnings

Latest Release
Dec 09, 2025
EPS / Forecast
0.10 / --
Revenue / Forecast
83.50M / --
EPS Revisions
Last 90 days

BLLN Income Statement

People Also Watch

20.91
AERO
-1.04%
17.91
EVMN
+4.68%
15.90
NAVN
0.00%
101.25
WSHP
-4.48%

FAQ

What Is the BillionToOne (BLLN) Stock Price Today?

The BillionToOne stock price today is 87.08

What Stock Exchange Does BillionToOne Trade On?

BillionToOne is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for BillionToOne?

The stock symbol for BillionToOne is "BLLN."

What Is the BillionToOne Market Cap?

As of today, BillionToOne market cap is 3.99B.

What Is BillionToOne's Earnings Per Share (TTM)?

The BillionToOne EPS (TTM) is -1.07.

When Is the Next BillionToOne Earnings Date?

BillionToOne will release its next earnings report on Feb 25, 2026.

From a Technical Analysis Perspective, Is BLLN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has BillionToOne Stock Split?

BillionToOne has split 0 times.

How Many Employees Does BillionToOne Have?

BillionToOne has 620 employees.

What is the current trading status of BillionToOne (BLLN)?

As of Dec 24, 2025, BillionToOne (BLLN) is trading at a price of 87.08, with a previous close of 87.08. The stock has fluctuated within a day range of 86.28 to 96.92, while its 52-week range spans from 86.28 to 138.70.

What Is BillionToOne (BLLN) Price Target According to Analysts?

The average 12-month price target for BillionToOne is USD137.83333, with a high estimate of USD160 and a low estimate of USD110. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +58.28% Upside potential.

What Is the BLLN Premarket Price?

BLLN's last pre-market stock price is 87.11. The pre-market share volume is 100.00, and the stock has decreased by 0.03, or 0.03%.

What Is the BLLN After Hours Price?

BLLN's last after hours stock price is 88.75, the stock has decreased by 1.68, or 1.92%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.